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ABSTRACT
Introduction: Correct use of inhalation devices
is critical for optimal drug delivery to the lower
lung. This Delphi process was conducted to
compile lists of potential handling errors when
using a Spiromax or Turbuhaler inhalation
device, as determined by an independent panel.
Methods: A Delphi process was used to obtain
consensus on potential handling errors for each
device from ten independent respiratory device
experts. In Round 1, advisors listed potential
errors with the devices. In Round 2, a severity
rating was assigned to each error based on
erroneous device handling negatively affecting
functionality and treatment effectiveness (error
[score 0–3]; potentially critical [4–7]; critical
[8–10]). In Round 3, advisors revised their
ratings based on the group scores and voted
on whether to accept the median severity score
as the consensus in Round 4.
Results: A total of 29 potential errors for
Spiromax and 31 for Turbuhaler were
identified in Round 1. After Round 4,
consensus was reached for 69% of the
Spiromax errors and 94% of the Turbuhaler
errors. After completion of the Delphi process,
some anomalies were identified in the list of
handling errors, which were then investigated
with the panel via teleconferences. After
teleconferences to discuss discrepancies in the
results, there were 22 errors for Spiromax (four
critical, 12 potentially critical, and six errors)
and 27 for Turbuhaler (nine critical, 14
potentially critical, and four errors). Not
inhaling through the mouthpiece, exhaling
into the device, and incorrect mouth
positioning were identified as critical errors for
both devices.
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Conclusion: Through the Delphi process,
advisors independently identified and reached
consensus on handling errors for Spiromax and
Turbuhaler. Fewer Spiromax errors were
classified as critical or potentially critical than
with Turbuhaler, indicating that there may be
less potential for handling errors with
Spiromax.
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INTRODUCTION
Respiratory diseases such as asthma and chronic
obstructive pulmonary disease (COPD) are
routinely managed using inhaled
bronchodilators and corticosteroids [1, 2].
However, the medication must reach the
receptors in the lower airways to exert its
effect. To ensure this happens, correct use of
the inhaler device is critical for optimal drug
delivery [3].
Patient-related factors such as poor
adherence and inhaler handling errors have a
negative impact on asthma control [4]. Studies
have shown that poor inhaler technique is
common and inhaler use is often highly
suboptimal [5]. Estimates of improper inhaler
use range from 20% to 82% of patients [4, 6–9].
There is increasing evidence in support of the
claim that correct inhaler technique is
fundamental for effective therapy and asthma
management [5, 10, 11]. Errors in the use of
inhalers have been shown to have serious
effects in terms of the management of the
disease [6, 8, 9]. Poor inhaler technique in
patients with asthma is associated with
increased hospitalization, more emergency
department visits, increased use of oral
corticosteroids and antimicrobials, and poorer
asthma control [6, 8, 9]. Some errors are
device-independent and include not breathing
out before actuation of the device [12].
Although correct inhaler technique involves
some common steps for all devices, the optimal
inhalation pattern differs between devices [3,
13]. Inhalers that are perceived as difficult to use
are usually associated with poor inhalation
technique and low treatment adherence,
leading to worsening in asthma control [14].
As such, the technical characteristics of an
inhaler device can determine how well it is
handled, and consequently, how often it is
correctly used. An inhaler that is easy to use,
intuitive, and preferred by the patient could
ultimately improve adherence [14–16].
In patients with inadequately controlled
asthma, the combination therapy involving an
inhaled corticosteroid (ICS) and a long-acting
b2 agonist (LABA) is a recommended therapy
[17]. The fixed-dose combination of the ICS/
LABA, budesonide/formoterol (BF), has proven
to be an effective therapy by improving
pulmonary function and asthma control [1, 2]
in patients with asthma and COPD. DuoResp
(BF) Spiromax (Teva Pharmaceuticals) is a BF
dry powder inhaler designed to provide dose
equivalence with enhanced user-friendliness
compared to Symbicort (BF) Turbuhaler
(AstraZeneca) [18]. Both inhalers are approved
in Europe for the treatment of patients with
asthma and COPD (for whom an ICS/LABA
combination is indicated).
To determine which of these two inhalers
patients might find easiest to use correctly, it is
necessary to establish objective criteria by
which these inhaler devices are compared with
regards to their ease-of-use and potential
handling errors. In this study, practicing
clinicians with a specialty in device handling
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in asthma or COPD were asked to identify
potential handling errors for the Spiromax and
the Turbuhaler device. Subsequently, a Delphi
process was used to reach consensus on the
errors most likely to be critical for effective drug
delivery. A Delphi process was chosen because it
is an established tool for reaching a consensus
on a complex problem in a highly objective way
[19–21]. In the Delphi process, a peer group of
experts work together anonymously to reach
consensus on a complex problem as objectively
as possible.
The aims of this Delphi process study were to
independently establish what is considered an
error (for optimal drug delivery) when handling
empty versions of DuoResp Spiromax or
Symbicort Turbuhaler dry powder inhalers and




This study was conducted by InterPhase
Consult, an independent strategic consulting
firm, on behalf of Teva Pharmaceuticals Inc.
InterPhase Consult ensured that the
methodology and conduct of the study were
free from bias and Teva Pharmaceuticals had no
influence on the choice of advisors, design, and
administration of the Round 1–4
questionnaires, or the data analysis.
This Delphi process was initiated with
selection of the advisors and development of
the questionnaires, followed by four rounds of
the Delphi process and then data analysis
(Fig. 1). Per Office for Human Research
Protections (OHRP) approved assurance
created under 45 CFR 46.103, the protocol was
exempt from informed written consent because
(1) the research presented no more than
minimal risk of harm to subjects, (2) the
exemption did not adversely affect the rights
and welfare of the subjects, (3) the research
could not practicably be carried out without the
exemption and (4) whenever appropriate, the
subjects were provided with additional




Fifteen European advisors were identified.
Advisors were invited to participate until 10
had accepted, per the recommendations of
Delbecq et al. (1975) for panel selection when
performing a Delphi methodology study [22].
Please refer to the Appendix in the
supplementary material for additional details
on the advisors selection.
Delphi Process (Rounds 1–4)
Using the Delphi process, advisors were asked
via questionnaires to agree on a list of potential
inhaler usage errors and then rate them
according to the perceived impact each error
would have on effective drug delivery. Advisors
remained anonymous to each other until the
teleconferences. Questionnaires were developed
before the study by InterPhase analysts, but the
wording could be adapted during the course of
the study, if necessary, to ensure instructions to
the advisors were clear and the Delphi process
was able to achieve consensus. Advisors
responded to the questionnaires online using
the website SurveyMonkey (Palo Alto, CA,
USA). The Delphi process aimed to achieve
consensus (see Data Analysis below) on C90% of
all errors.
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Round 1
Participating advisors were sent empty
Spiromax and Turbuhaler devices along with
the respective patient instruction leaflets. Once
they were familiar with the devices and their
instructions, the advisors were asked to list all of
the potential handling errors they could think
of for each device. Handling errors were defined
as any way in which the inhaler could be used
incorrectly during the inhalation process. The
advisors were randomly divided into two
groups; one group reviewed the Spiromax
device first and the other reviewed the
Turbuhaler device first. The resultant lists from
the 10 advisors were consolidated by InterPhase
Consult into one list of errors for each device.
Round 2
Advisors received the consolidated list of errors
(ordered randomly) and were asked to score
each error with respect to its severity using an
integer scale of 0–10, (0, least critical; 10, most
critical). The severity levels were then separated
into three categories: ‘error’, ‘potentially
critical’, and ‘critical’ as shown in Fig. 2. Based
on the advisors’ expert opinion with regards to
the impact on treatment outcomes and/or
inhaler device functionality, ‘error’ indicated
an error that would have minor or no impact,
‘potentially critical’ indicated an error would
have a mild-to-moderately negative impact, and
‘critical’ indicated an error would have a
negative impact. An error could be removed
from the list if seven or more advisors provided
approval. Advisors were also asked to give their
reasoning behind the score they assigned for
each error.
Round 3
Advisors were given an individualized report
showing their responses relative to the
consolidated group severity scores and were
given the opportunity to re-evaluate their scores
and revise them if they wished. If a consensus
was not achieved for C90% of errors for each
device, a fourth round was to be conducted.
Round 4
Advisors were provided with a list of all errors
grouped within their corresponding categories
as determined by the median score from Round
3. They were then asked to agree or disagree
with the error category for each error based on
the median error severity ranking from Round
Fig. 1 Outline of the
study processes
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3. The outcome from Round 3 was accepted as
consensus group opinion if C90% of the
advisors agreed in Round 4.
Post-hoc Study Amendment
In a post hoc study amendment, advisors were
asked to participate in a series of teleconferences
to discuss and refine the output from the Delphi
process. A summary of the consensus from the
calls was subsequently approved by the
participating advisors.
Data Analysis
Scores obtained for each error in Rounds 2 and 3
were analyzed using descriptive statistics and
median scores were calculated using Microsoft
Excel 2010 software (Microsoft, Redmond,
USA). Errors were ranked according to median
scores within each of the three severity
categories. Interquartile ranges (IQRs) were
calculated to give a measure of dispersion and,
therefore, consensus. Consensus for each error
was deemed to have been reached when the IQR
was B2, or if C80% of advisors put the error into
the same severity category.
RESULTS
Conduct of the Study
Ten advisors participated in this study
(Table S1). Full consensus was not reached for
C90% of the errors after Round 3; a fourth
round was conducted. Some changes were made
to the wording and design of the questionnaire
following Round 1 to emphasize the intended
meaning and definition of a handling error.
Identification of Errors Using the Delphi
Process (Rounds 1–4)
Round 1
A total of 29 potential errors were identified for
Spiromax in Round 1 and 31 were identified for
Turbuhaler (data on file, Teva Pharmaceuticals
and InterPhase Consult).
Rounds 2 and 3
None of the errors was deemed to be invalid by
seven or more advisors in Round 2 and all were
retained.
Median severity scores were assigned to each
of the errors and did not change significantly
between Rounds 2 and 3 (Table 1). A critical
severity score was given on fewer occasions for
errors in using Spiromax compared with
Turbuhaler.
The errors considered by the advisors to be
most critical (median severity score of C9) when
using Turbuhaler were ‘not inhaling through
the mouthpiece (e.g., nose)’, ‘difficulty/failure
to remove the cap prior to usage’, ‘forgetting to
load the device prior to each dosage’, and
‘exhaling into the device’. The error ‘forgetting
to load the device prior to each dosage’ was
assigned to the critical error category by all ten
advisors; nine advisors put ‘exhaling into the
device’, ‘not inhaling through the mouthpiece
Fig. 2 Integer scale
used to rate error
severity
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Table 1 Final error categorization and Round 2 and 3 severity scoresa for (A) Spiromax and (B) Turbuhaler
(A) Spiromax






Not inhaling through the mouthpiece (e.g., nose) Critical 9.5 (2.00) 9.5 (1.00)
Failure to read the dose indicator correctly, potentially leading
to use of empty device
Critical 9.0 (1.00) 9.0 (0.25)
Exhaling into the device Critical 8.0 (1.50) 8.0 (2.00)
Incorrect positioning of mouth, lips, or tongue—resulting in
incomplete or failed inhalation
Critical 7.0 (4.50) 8.0 (7.00)
Inhalation insufﬁciently deep Potentially
critical
7.0 (4.00) 7.0 (3.00)




7.0 (3.00) 7.0 (2.75)
Mouthpiece not folded down sufﬁciently to load device Potentially
critical
7.0 (5.25) 7.0 (3.75)




7.0 (4.00) 7.0 (2.50)
Blocking the air vent during inhalation with ﬁngers/lips Potentially
critical
6.5 (2.75) 6.0 (2.00)
Storing the device in a hot/humid area with the cap off Potentially
critical
6.5 (3.25) 6.0 (2.00)
Inhalation insufﬁciently rapid Potentially
critical
6.0 (4.00) 6.5 (2.25)
Forgetting to close mouthpiece cover after usage Potentially
critical
4.0 (3.00) 5.0 (3.00)




4.0 (6.50) 4.5 (4.50)
Unable to/forgetting to breathe out fully prior to inhalation Potentially
critical
4.0 (1.00) 4.5 (1.25)
Unable to/forgetting to hold the breath following inhalation Potentially
critical
4.0 (3.00) 4.0 (2.50)
Inhalation too rapid Potentially
critical
4.0 (3.00) 4.0 (3.50)
Device not held upright during loading/inhalation Error 4.0 (4.00) 4.0 (4.00)
Not holding breath for long enough following inhalation Error 4.0 (3.00) 4.0 (2.00)
Unable to hear the click when opening the mouthpiece to
indicate that the device is ready to use
Error 3.0 (3.50) 3.0 (1.50)
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Table 1 continued
(A) Spiromax






Forgetting to rinse mouth after inhalation Error 3.0 (2.00) 3.0 (2.25)
Playing around with mouthpiece between uses, wasting doses Error 2.0 (1.00) 2.0 (3.00)
Opening the mouthpiece by moving the body of the device
downwards
Error 1.0 (5.00) 1.0 (3.00)
(B) Turbuhaler






Difﬁculty/failure to remove the cap prior to usage Critical 10.0 (2.50) 10.0 (1.00)
Not inhaling through the mouthpiece (e.g., nose) Critical 9.5 (2.00) 10.0 (1.00)
Forgetting to load the device prior to each dosage Critical 9.5 (2.00) 9.5 (1.75)
Exhaling into the device Critical 9.0 (1.50) 9.0 (0.75)
Holding the mouthpiece instead of the barrel when
twisting the red grip
Critical 8.0 (4.25) 8.5 (1.75)
Failure to read the dose indicator correctly, potentially
leading to using an empty device
Critical 8.0 (0.75) 8.0 (0.75)
Red grip is only rotated fully in one direction prior to
using the device
Critical 8.0 (2.50) 8.0 (1.75)
Incorrect positioning of the mouth, lips, or tongue—
resulting in incomplete or failed inhalation
Critical 8.0 (1.00) 8.0 (2.00)
Failing to fully rotate the red grip Critical 6.5 (2.75) 8.0 (2.75)
Loading the device when it is not held upright Potentially
critical
7.0 (3.75) 7.0 (1.75)
When two doses are required, loading the device only
once but inhaling twice
Potentially
critical
7.0 (3.00) 7.0 (3.00)
Twisting the red grip whilst inhaling Potentially
critical
7.0 (3.00) 6.5 (2.75)
Inhalation insufﬁciently deep Potentially
critical
6.0 (2.75) 6.0 (2.00)
Inhalation insufﬁciently rapid Potentially
critical
6.0 (3.25) 6.0 (3.50)
Storing the device in a hot/humid area with the cap off Potentially
critical
6.0 (2.00) 6.0 (0.00)
Inability to feel the drug upon inhalation, causing patient
to repeat the process
Potentially
critical
6.0 (4.00) 6.0 (4.00)
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(e.g., nose)’, ‘red grip is only rotated fully in one
direction prior to using the device’, and
‘holding the mouthpiece instead of the barrel
when twisting the red grip’ in the critical error
category.
For Spiromax, the errors considered to be
most critical were ‘not inhaling through the
mouthpiece (e.g., nose)’ and ‘failure to read the
dose indicator correctly, potentially leading to
using an empty device’. None of the errors were
classified as being critical by all 10 advisors;
eight advisors classed ‘not inhaling through the
mouthpiece (e.g., nose)’ as a critical error.
After Round 3, consensus was reached for
38% of the errors for Spiromax and 68% of the
errors for Turbuhaler.
Round 4
In Round 4, the median severity scores from
Round 3 were accepted as the consensus for an
Table 1 continued
(B) Turbuhaler






When two doses are required, loading the device twice
but inhaling only once
Potentially
critical
5.0 (2.75) 6.5 (2.50)




5.0 (1.00) 5.0 (1.00)
Device not held horizontally during inhalation Potentially
critical
5.0 (3.00) 4.0 (2.50)
Inhalation too rapid Potentially
critical
4.5 (4.00) 4.0 (3.00)




4.0 (4.00) 4.0 (1.00)




3.5 (2.75) 4.0 (2.00)





Rotating red grip more times than is required Error 3.0 (2.50) 3.0 (2.00)
Forgetting to rinse mouth after inhalation Error 3.0 (2.00) 3.0 (0.00)
Forgetting to put the cap back on completely after usage Error 3.0 (3.75) 3.0 (3.50)
Not holding breath for long enough following
inhalationa
Error – –
The wording of some of the errors was modiﬁed slightly between Round 3 and the ﬁnal categorization
IQR interquartile range
a Scoring on scale of 0–10 with deﬁned boundaries of what constitutes ‘critical’ (8–10/10), ‘potentially critical’ (4–7/10),
‘error’ (0–3/10)
b Error was added following the teleconferences after Round 4 of the Delphi process
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additional nine errors for Spiromax and eight
errors for Turbuhaler, resulting in 69%
consensus for Spiromax and 94% for
Turbuhaler.
Post-hoc Review and Analysis
A post-hoc review (by InterPhase Consult and
Teva Pharmaceuticals) of the errors identified
for Spiromax and Turbuhaler found some
anomalies, such as: handling errors that had
been scored differently for the two devices, but
which may reasonably have been expected to be
scored consistently; handling errors that had
been scored consistently, but which may
reasonably have been expected to have been
scored differently; and handling errors that may
be invalid based on the definition of a handling
error. Following this review, all advisors were
invited to attend a teleconference to discuss the
results. Six advisors agreed to participate and
two teleconferences were held to discuss the
output of the Delphi process and the anomalies,
and to give the advisors an opportunity to revise
their scores. After the teleconferences, a
summary of the consensus from the calls was
sent to the participating advisors for their
approval.
A total of 16 errors were identified as being
anomalous and were discussed. After the calls,
four of these retained their original
classification and 12 were reclassified. For
Spiromax, six errors were removed, as they
were not thought to be valid handling errors
for the device, and two potentially critical errors
were reclassified as non-critical errors (not
holding the breath for long enough following
inhalation; device not held upright during
loading/inhalation). For Turbuhaler, five errors
were removed, as they were not thought to be
valid handling errors for the device, and two
errors that had originally only been identified
for Spiromax were added (not holding the
breath for long enough following inhalation;
unable to/forgetting to breathe out fully prior to
inhalation).
Final Outcome
Following the teleconferences, the number of
potential handling errors was finalized as 22 for
Spiromax and 27 for Turbuhaler (Table 1;
Fig. 3). Based on the group median scores from
Round 3 and the subsequent error
categorization during the teleconferences, the
22 potential handling errors for Spiromax
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comprised four critical errors, 12 potentially
critical errors, and six non-critical errors
(Table 1; Fig. 3). In comparison, the 27
potential handling errors for Turbuhaler
comprised nine critical errors, 14 potentially
critical errors, and four non-critical errors
(Table 1; Fig. 3).
DISCUSSION
Despite the availability of a wide variety of
medications, a significant portion of patients
with asthma and COPD remain uncontrolled
[14–16]. The correct use of an inhaler device is
crucial for optimal drug delivery. As such, the
inhaler device itself plays an important and
active role in asthma management. It is
therefore important to have devices which are
intuitive to use and to train patients.
Using the Delphi process, advisors
participating in this study independently
identified potential handling errors for Spiromax
and Turbuhaler and ranked them according to
their severity. Spiromaxwas associated with fewer
errors overall (22 vs. 27) and fewer errors thatwere
classified as critical (four vs. nine) or potentially
critical (12 vs. 14) than Turbuhaler. This suggests
that there may be less potential for critical
handling errors when using the Spiromax device
compared with Turbuhaler.
Findings from this study are in agreement
with outcomes reported in two independent
device mastery studies among healthy Finnish
volunteers and healthcare practitioners (HCPs)
in Australia. In healthy adult Finnish volunteers
[23] and Australian HCPs [24], Spiromax was
associated with higher levels of device mastery
and fewer errors by intuitive use/no instructions
and after reading the patient information leaflet
compared with Turbuhaler.
Training patients in inhaler use is a core
component of good clinical practice [25].
Consequently, providing HCPs with an inhaler
that is less prone to device handling errors and
easy to use and teach patients could potentially
reduce the number of device handling errors
and ultimately improve asthma control. Results
from this study highlight specific errors that
could potentially be committed using Spiromax
or Turbuhaler. Two errors for Turbuhaler
received the maximum median severity score
of 10; these were ‘not inhaling through the
mouthpiece (e.g., nose)’ and ‘difficulty/failure
to remove the cap prior to usage’. A number of
errors regarding priming of the device were
classified as critical for Turbuhaler (which were
not identified for Spiromax). These included,
‘forgetting to load the device prior to each
dosage’, ‘failing to fully rotate the red grip’,
‘failure to read the dose indicator correctly,
potentially leading to using an empty device’,
and ‘red grip is only rotated fully in one
direction prior to using the device’. The
highest median severity score for a Spiromax
error was 9.5 for ‘not inhaling through the
mouthpiece (e.g., nose)’. Thus, HCPs should
focus on these potential errors when training
patients to use Spiromax or Turbuhaler.
Although training in inhaler technique is
important and assessing technique is
recommended at every visit [25], in everyday
life this might not prove practical or possible.
Additionally, training alone might not be
sufficient to ensure proper technique mastery.
Some patients fail to achieve correct inhaler
technique despite repetitive training [3]. The
patient’s opinion on a particular device,
psychosocial factors such as preference and
willingness to use a particular device, and the
device choice are also important aspects to
consider [26]. The ability to use the inhaler
correctly can influence adherence [3]. An
intuitive device that is easy to use and
preferred by the patient might also improve
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asthma control by minimizing the risk of
handling error committed by the patient and
improving adherence. However, it is important
to note that a device that is shown to
potentially be associated with fewer errors in
an experimental setting does not necessarily
translate to less potential errors and better
inhalation technique in real life. Also, a device
with less potential errors is not automatically
the preferred device by the patient. Real-life
scenarios can be different and several
patient-related factors such as comorbidities,
dexterity, familiarity with inhaler devices, and
other lifestyle factors may play a role [8, 27].
Matching the correct patient with the correct
inhaler is now thought to be essential when
prescribing an inhaler that a patient can and
will use correctly at every use [28, 29].
The Delphi process methodology was
deemed most suitable for this study because it
is an established tool for reaching consensus on
a complex problem as objectively as possible. It
has been proven to be effective for reaching a
consensus when factual data do not exist or
cannot easily be obtained, or when the problem
is so subjective that an individual may give an
opinion that conforms to those of other
participants rather than maintaining their own
critical opinion [19, 30]. Among the strengths of
this study are the key characteristics of the
Delphi process: the involvement of an expert
panel, the anonymity of the advisors and their
responses to other participants, the use of a
series of questionnaires administered in rounds,
the summarization of information from each
round via a moderator and sharing of
anonymized group opinion, the progressive
convergence of opinions with administration
of each questionnaire, and quantification of the
extent of agreement using simple statistics.
This study has a number of limitations, one
of which was the requirement for the
teleconferences after Round 4 of the Delphi
process to finalize the lists of potential handling
errors. It was felt necessary to conduct the
teleconferences for a number of reasons: there
was\90% consensus for the errors for
Spiromax; some of the listed errors were not
thought to be valid handling errors while others
were thought to unfairly disadvantage one
device over another; and some errors were
listed for one device that should be applicable
to both. Examples of invalid handling errors
that were removed include: ‘washing the device
using liquids/getting the device wet’, ‘chewing
the mouthpiece of the device’, ‘information
leaflet inaccurate/difficult to understand’, and
‘attempting to fit a spacer device’. The need for
the teleconferences may be interpreted as
interference in the Delphi process; however,
neither device was unfairly prejudiced by the
teleconferences—both devices had some errors
removed by the advisors. The aim of the
teleconferences was to ensure the final error
lists were accurate and representative of
handling characteristics of the devices in the
real world.
Other limitations include that the
respiratory device experts chosen as advisors
may not have been able to identify all of the
handling errors that may occur in daily usage of
the devices owing to their inherent expertise. As
such, the findings from this study rely on the
judgment of a select group who are experts in
the field and may not be representative of the
wider healthcare community. Additionally, the
Delphi process employs a consensus approach.
Extreme positions are usually eliminated and
the outcome may be a diluted version of the
overall expressed opinions.
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CONCLUSIONS
Through the Delphi process, experts in
respiratory devices independently identified
and reached consensus on potential handling
errors for Spiromax and Turbuhaler and their
severity. ‘Not inhaling through the mouthpiece
(e.g., nose)’ was one of the most highly rated
critical errors for both devices. Critical errors in
priming the device were identified for
Turbuhaler, but not for Spiromax, as might be
expected given the difference in operation of
the two devices. There were fewer errors
identified overall for Spiromax compared with
Turbuhaler, and fewer errors with Spiromax
were classified as critical or potentially critical
than with Turbuhaler. Altogether, this indicates
that there may be less potential for critical
errors with Spiromax than Turbuhaler.
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